SEC Company Response from BioPharmX Corp (CIK 0001504167) — Aug 3, 2022
BioPharmX Corp (CIK 0001504167)
Date: Aug. 3, 2022 · CIK: 0001504167 · Accession: 0001104659-22-085496
AI Filing Summary & Sentiment
File numbers found in text: 333-265974
Letter
Re: Timber Pharmaceuticals, Inc. (the “Company”)
August 3, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (File No. 333-265974)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 9:00 a.m., Eastern Time, on August 4, 2022, or as soon as practicable thereafter.
Please call Alan Wovsaniker of Lowenstein Sandler LLP at 973-597-2564 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
TIMBER PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
August 3, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Timber Pharmaceuticals, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-265974)
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration
Statement”) be declared effective by the Securities and Exchange Commission at 9:00 a.m., Eastern Time, on August 4, 2022, or as
soon as practicable thereafter.
Please call Alan Wovsaniker
of Lowenstein Sandler LLP at 973-597-2564 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
TIMBER PHARMACEUTICALS, INC.
By:
/s/ John Koconis
Name:
John Koconis
Title:
Chief Executive Officer